osteoporosis research ltd
osteoporosis research ltd Company Information
Company Number
07932529
Next Accounts
Dec 2025
Shareholders
john anthony kanis
rebecca louise kanis-buck
Group Structure
View All
Industry
Manufacture of basic pharmaceutical products
Registered Address
1st floor sackville house, 143-149 fenchurch street, london, EC3M 6BL
Website
-osteoporosis research ltd Estimated Valuation
Pomanda estimates the enterprise value of OSTEOPOROSIS RESEARCH LTD at £1.4m based on a Turnover of £1.2m and 1.1x industry multiple (adjusted for size and gross margin).
osteoporosis research ltd Estimated Valuation
Pomanda estimates the enterprise value of OSTEOPOROSIS RESEARCH LTD at £423.7k based on an EBITDA of £89.9k and a 4.71x industry multiple (adjusted for size and gross margin).
osteoporosis research ltd Estimated Valuation
Pomanda estimates the enterprise value of OSTEOPOROSIS RESEARCH LTD at £697.8k based on Net Assets of £399.7k and 1.75x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Osteoporosis Research Ltd Overview
Osteoporosis Research Ltd is a live company located in london, EC3M 6BL with a Companies House number of 07932529. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in February 2012, it's largest shareholder is john anthony kanis with a 50% stake. Osteoporosis Research Ltd is a established, small sized company, Pomanda has estimated its turnover at £1.2m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Osteoporosis Research Ltd Health Check
Pomanda's financial health check has awarded Osteoporosis Research Ltd a 2 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 6 areas for improvement. Company Health Check FAQs
1 Strong
3 Regular
6 Weak
Size
annual sales of £1.2m, make it smaller than the average company (£34.5m)
- Osteoporosis Research Ltd
£34.5m - Industry AVG
Growth
3 year (CAGR) sales growth of 6%, show it is growing at a similar rate (5.5%)
- Osteoporosis Research Ltd
5.5% - Industry AVG
Production
with a gross margin of 20.4%, this company has a higher cost of product (35.8%)
- Osteoporosis Research Ltd
35.8% - Industry AVG
Profitability
an operating margin of 7.3% make it as profitable than the average company (7.4%)
- Osteoporosis Research Ltd
7.4% - Industry AVG
Employees
with 6 employees, this is below the industry average (116)
6 - Osteoporosis Research Ltd
116 - Industry AVG
Pay Structure
on an average salary of £63.4k, the company has an equivalent pay structure (£63.4k)
- Osteoporosis Research Ltd
£63.4k - Industry AVG
Efficiency
resulting in sales per employee of £206.5k, this is less efficient (£414.6k)
- Osteoporosis Research Ltd
£414.6k - Industry AVG
Debtor Days
it gets paid by customers after 124 days, this is later than average (63 days)
- Osteoporosis Research Ltd
63 days - Industry AVG
Creditor Days
its suppliers are paid after 7 days, this is quicker than average (32 days)
- Osteoporosis Research Ltd
32 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Osteoporosis Research Ltd
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Osteoporosis Research Ltd
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 5.1%, this is a lower level of debt than the average (43.6%)
5.1% - Osteoporosis Research Ltd
43.6% - Industry AVG
OSTEOPOROSIS RESEARCH LTD financials
Osteoporosis Research Ltd's latest turnover from March 2024 is estimated at £1.2 million and the company has net assets of £399.7 thousand. According to their latest financial statements, Osteoporosis Research Ltd has 6 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Dec 2013 | Feb 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||||||
| Other Income Or Grants | ||||||||||||
| Cost Of Sales | ||||||||||||
| Gross Profit | ||||||||||||
| Admin Expenses | ||||||||||||
| Operating Profit | ||||||||||||
| Interest Payable | ||||||||||||
| Interest Receivable | ||||||||||||
| Pre-Tax Profit | ||||||||||||
| Tax | ||||||||||||
| Profit After Tax | ||||||||||||
| Dividends Paid | ||||||||||||
| Retained Profit | ||||||||||||
| Employee Costs | ||||||||||||
| Number Of Employees | 6 | 6 | 6 | 6 | 5 | 4 | 3 | 3 | ||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Dec 2013 | Feb 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 14,385 | 4,475 | 5,075 | 5,675 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 99 | 99 | 99 | 99 | 99 | 99 | 99 | 99 | 99 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 99 | 99 | 14,484 | 4,574 | 5,174 | 5,774 | 99 | 99 | 99 | 0 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 420,960 | 340,627 | 428,160 | 311,450 | 355,856 | 503,887 | 372,063 | 277,569 | 452,377 | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 356,840 | 21,944 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 420,960 | 340,627 | 428,160 | 311,450 | 355,856 | 503,887 | 372,063 | 277,569 | 452,377 | 356,840 | 21,944 | 0 |
| total assets | 421,059 | 340,726 | 442,644 | 316,024 | 361,030 | 509,661 | 372,162 | 277,668 | 452,476 | 356,840 | 21,944 | 0 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 21,389 | 8,506 | 24,780 | 8,824 | 8,714 | 41,888 | 53,446 | 36,856 | 119,096 | 89,385 | 27,220 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 21,389 | 8,506 | 24,780 | 8,824 | 8,714 | 41,888 | 53,446 | 36,856 | 119,096 | 89,385 | 27,220 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 21,389 | 8,506 | 24,780 | 8,824 | 8,714 | 41,888 | 53,446 | 36,856 | 119,096 | 89,385 | 27,220 | 0 |
| net assets | 399,670 | 332,220 | 417,864 | 307,200 | 352,316 | 467,773 | 318,716 | 240,812 | 333,380 | 267,455 | -5,276 | 0 |
| total shareholders funds | 399,670 | 332,220 | 417,864 | 307,200 | 352,316 | 467,773 | 318,716 | 240,812 | 333,380 | 267,455 | -5,276 | 0 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Dec 2013 | Feb 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Operating Profit | ||||||||||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Tax | ||||||||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 80,333 | -87,533 | 116,710 | -44,406 | -148,031 | 131,824 | 94,494 | -174,808 | 452,377 | 0 | 0 | 0 |
| Creditors | 12,883 | -16,274 | 15,956 | 110 | -33,174 | -11,558 | 16,590 | -82,240 | 29,711 | 89,385 | 27,220 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | ||||||||||||
| Investing Activities | ||||||||||||
| capital expenditure | ||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 99 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||
| Financing Activities | ||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||
| interest | ||||||||||||
| cash flow from financing | ||||||||||||
| cash and cash equivalents | ||||||||||||
| cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -356,840 | 356,840 | 21,944 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -356,840 | 356,840 | 21,944 | 0 |
osteoporosis research ltd Credit Report and Business Information
Osteoporosis Research Ltd Competitor Analysis
Perform a competitor analysis for osteoporosis research ltd by selecting its closest rivals, whether from the MANUFACTURING sector, other small companies, companies in EC3M area or any other competitors across 12 key performance metrics.
osteoporosis research ltd Ownership
OSTEOPOROSIS RESEARCH LTD group structure
Osteoporosis Research Ltd has no subsidiary companies.
Ultimate parent company
OSTEOPOROSIS RESEARCH LTD
07932529
osteoporosis research ltd directors
Osteoporosis Research Ltd currently has 3 directors. The longest serving directors include Professor John Kanis (Feb 2012) and Ms Rebecca Kanis-Buck (Jan 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Professor John Kanis | England | 80 years | Feb 2012 | - | Director |
| Ms Rebecca Kanis-Buck | England | 50 years | Jan 2019 | - | Director |
| Professor Eugene McCloskey | 65 years | Jul 2021 | - | Director |
P&L
March 2024turnover
1.2m
+13%
operating profit
89.9k
0%
gross margin
20.5%
+1.03%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
399.7k
+0.2%
total assets
421.1k
+0.24%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
osteoporosis research ltd company details
company number
07932529
Type
Private limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
incorporation date
February 2012
age
13
incorporated
UK
ultimate parent company
accounts
Micro-Entity Accounts
last accounts submitted
March 2024
previous names
iof research limited (November 2013)
accountant
-
auditor
-
address
1st floor sackville house, 143-149 fenchurch street, london, EC3M 6BL
Bank
-
Legal Advisor
-
osteoporosis research ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to osteoporosis research ltd.
osteoporosis research ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for OSTEOPOROSIS RESEARCH LTD. This can take several minutes, an email will notify you when this has completed.
osteoporosis research ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
